ADMA Biologics
ADMA
19 hedge funds and large institutions have $68.5M invested in ADMA Biologics in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
46% more funds holding
Funds holding: 13 → 19 (+6)
3% more capital invested
Capital invested by funds: $66.8M → $68.5M (+$1.75M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$5.79M |
| 2 |
PC
PointState Capital
New York
|
+$2.05M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.22M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$1.1M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$826K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.75M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$26.6K |
| 3 |
US Bancorp
Minneapolis,
Minnesota
|
-$22K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$6.05K |
| 5 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$5.58K |
ADMA Hedge Fund Activity: Q1 2015 in Review
19 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2015, worth a combined $68.5M — up 2.6% from $66.8M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ADMA positions and 3 closed out — a net gain of 6 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $5.79M. The largest seller was Sio Capital Management, exiting entirely with an estimated $2.75M sold.
- 19 institutional investors held ADMA Biologics (ADMA) as of Q1 2015, up from 13 in Q4 2014.
- Funds reported $68.5M of ADMA Biologics stock for Q1 2015, up 2.6% quarter-over-quarter.
- 9 funds opened new ADMA Biologics positions in Q1 2015 and 3 closed out, a net change of +6 holders.
- The largest ADMA Biologics buyer in Q1 2015 was Broadfin Capital, an estimated $5.79M added.
- The largest ADMA Biologics seller in Q1 2015 was Sio Capital Management, an estimated $2.75M sold.
Based on aggregated 13F filings for Q1 2015.